Sponsors Drive CARs To The Next Destination: Pivotal Trials
With proof of high response rates in small studies of B-cell malignancies in the rear view, sponsors focus on the next hurdles – launching potentially registrational studies in 2015, honing plans for a smooth-running manufacturing process and branching out into new indications.
You may also be interested in...
J.P. Morgan Notebook, Jan. 14: Kite, Cellectis And MannKind
Round-up of news and notes from the last presentations at the 2016 J.P. Morgan Healthcare Conference in San Francisco.
J.P. Morgan Notebook, Jan. 11: Pfizer/Allergan, Celgene, Gilead And More
Daily round-up of news and notes from the 2016 J.P. Morgan Healthcare Conference in San Francisco.
Where Does Novartis Go From Here In Oncology? A Conversation With Its Oncology, Gene Therapy Execs
Novartis may be behind other big rivals that already have immuno-oncology therapies on the market but its top R&D scientists Alessandro Riva and Usman Azam say it can leap frog to a front position using its early IO pipeline and targeted cancer drugs.